Literature DB >> 10216172

Effects of growth factors on the hair cells after ototoxic treatment of the neonatal mammalian cochlea in vitro.

R Romand1, S Chardin.   

Abstract

The aim of this study was to test the possible regenerative potential of several molecules and growth factors such as retinoic acid (RA), insulin, epidermal growth factor (EGF) and transforming growth factors alpha (TGFalpha) and beta (TGFbeta) on the neonatal cochlea in vitro after neomycin intoxication. Our studies show that cochlear sensory epithelium behaves differently while maintained in various culture conditions, although we did not observe regeneration whatever the molecules or growth factors tested. The ototoxic action of neomycin in vitro produced a specific death of hair cells, except in the apical region. Organ of Corti of rats 3 days after birth always presented two regions that responded differently to the antibiotic: a widespread scar region extending from the basal cochlea up to the beginning of the apical turn, where most hair cells had disappeared, and a second region called the resistance region localized in the apex, and which was more or less developed depending on culture conditions. The length of the resistance region was modulated by molecules or growth factors added to the feeding solution suggesting that some of them could produce a protective action on hair cells against neomycin. Slight protection effects may be found with RA and insulin, however, the most definite protection results from the combination of insulin with TGFalpha as shown by the large increase in the length of the resistance region compared to organ of Corti treated with antibiotic alone. The tested molecules and growth factors did not promote cochlear hair cell regeneration in vitro after neomycin treatment, however some of them may offer a protective action against ototoxicity. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216172     DOI: 10.1016/s0006-8993(99)01211-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  EGFR signaling is required for regenerative proliferation in the cochlea: conservation in birds and mammals.

Authors:  Patricia M White; Jennifer S Stone; Andrew K Groves; Neil Segil
Journal:  Dev Biol       Date:  2012-01-02       Impact factor: 3.582

2.  Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial.

Authors:  Takayuki Nakagawa; Tatsunori Sakamoto; Harukazu Hiraumi; Yayoi S Kikkawa; Norio Yamamoto; Kiyomi Hamaguchi; Kazuya Ono; Masaya Yamamoto; Yasuhiko Tabata; Satoshi Teramukai; Shiro Tanaka; Harue Tada; Rie Onodera; Atsushi Yonezawa; Ken-ichi Inui; Juichi Ito
Journal:  BMC Med       Date:  2010-11-25       Impact factor: 8.775

3.  Sox2-CreER mice are useful for fate mapping of mature, but not neonatal, cochlear supporting cells in hair cell regeneration studies.

Authors:  Bradley J Walters; Tetsuji Yamashita; Jian Zuo
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

4.  A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment.

Authors:  Takayuki Nakagawa; Kozo Kumakawa; Shin-ichi Usami; Naohito Hato; Keiji Tabuchi; Mariko Takahashi; Keizo Fujiwara; Akira Sasaki; Shizuo Komune; Tatsunori Sakamoto; Harukazu Hiraumi; Norio Yamamoto; Shiro Tanaka; Harue Tada; Michio Yamamoto; Atsushi Yonezawa; Toshiko Ito-Ihara; Takafumi Ikeda; Akira Shimizu; Yasuhiko Tabata; Juichi Ito
Journal:  BMC Med       Date:  2014-11-19       Impact factor: 8.775

5.  Protein Synthesis Inhibition and Activation of the c-Jun N-Terminal Kinase Are Potential Contributors to Cisplatin Ototoxicity.

Authors:  Brian D Nicholas; Shimon Francis; Elizabeth L Wagner; Sibo Zhang; Jung-Bum Shin
Journal:  Front Cell Neurosci       Date:  2017-09-27       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.